O-1602

O-1602 is an agonist of GPR55 (G protein-coupled receptor 55). O-1602 reduces the number and activation of hippocampal microglia induced by METH (methamphetamine). O-1602 decreases the expression levels of NLRP3 inflammasome proteins, including NLRP3, ASC and Caspase-1^[1]. In Vitro:O-1602 (10 μM and 100 μM; 10 days) increases intracellular calcium levels, promotes lipid accumulation, and increases the expression of CEBP-α, a key regulator of adipocyte differentiation at 100 μM^[2].
O-1602 (0 μM and 10 μM; 10 days) promotes the accumulation of lipid in 3T3-L1 adipocytes^[2].
In Vivo:O-1602 (10 mg/kg, ip; once daily for 14 consecutive days) decreases levels of serum corticosterone, TNF-α, IL-1β, and IL-6 ^[1].
O-1602 (10 mg/kg, ip; once daily for 14 consecutive days) increases hippocampal GPR55 protein expression ^[1].
O-1602 (10 mg/kg, ip; once daily for 14 consecutive days) significantly increases DCX expression in the DG ^[1].
O-1602 (10 mg/kg, ip; once daily for 14 consecutive days) significantly decreases the number of microglia in the hippocampus ^[1].
O-1602 (10 mg/kg, ip; once daily for 14 consecutive days) increases expression levels of NLRP3, ASC, and Caspase-1 in the hippocampus ^[1].
O-1602 (0.1 mg/kg,ip; subchronically infused for 7 days) decreases the percentage of fat utilization over total energy consumption and decreases metabolic use of lipids leading to elevated fat deposition rates^[2].
O-1602 (0.04 and 0.4 μg/h/rat, ip; for 7 days) increases the the amount of fat mass with O-1602 at the dose of 0.4 μg/h/rat^[2].